WHERE DOES THE MONEY GO?
Our mission?
To fund Australia’s brightest and most innovative medical researchers...
Our aspiration?
To ensure Precision Medicine for ALL new cancer patients...
What is Precision Medicine?
Every cancer is different for every body. Precision Medicine...
Here are the incredible cancer vanquishing projects we support.
THE CONNIE JOHNSON BREAST CANCER RESEARCH LABORATORY
INSTITUTE:
The Garvan Institute of Medical Research
CHIEF RESEARCHERS:
Assoc. Prof. Elgene Lim & Assoc. Prof. Alex Swarbrick
DATE:
2013 - extant
The Connie Johnson Laboratory performs clinically focused laboratory research, aiming to better understand the heterogeneity in breast cancer, and identifying novel ways to treat breast cancer.
Patients are key partners in this endeavour, and Assoc. Prof. Elgene Lim and Assoc. Prof. Alex Swarbrick engage patients to donate a sample of their tumour tissue to be used for research. The grant is directed, in the first instance, toward establishing the necessary infrastructure to maximise patient-centric research, broadly called Project SHARE (Specimens Help All Research Efforts). The grant will also be used to expand the Cancer Sampling Program for autopsies on patients who have died from advanced breast, prostate, lung and pancreatic cancers. Finally, the grant will establish Clinical Trials Connect, a digital platform to help cancer patients navigate current clinical trials and to connect patients with researchers.
2021 - extant
THE ZERO CHILDHOOD CANCER PROGRAM
INSTITUTION:
An initiative of Children’s Cancer Institute and Kids Cancer Centre at Sydney Children’s Hospital, Randwick
CHIEF RESEARCHER:
Prof. Glenn Marshall AM
SYNOPSIS:
The Zero Childhood Cancer program aims to one day be able to provide a personalised treatment plan for every child.
2020 - 2023
USING POLYGENIC RISK MODIFICATION TO IMPROVE BREAST CANCER PREVENTION: THE PRIMO TRIAL.
INSTITUTION:
Peter MacCallum Cancer Centre
CHIEF RESEARCHER:
A/Prof. Paul James
SYNOPSIS:
Genomic testing will be used to identify women who can benefit the most from preventative strategies. Outcomes from this study will lead to the implementation of personalised risk management.
2021 - 2023
IDENTIFYING TARGETS ON MYELOID CELLS TO DESIGN PERSONALISED COMBINATION IMMUNOTHERAPIES FOR TRIPLE-NEGATIVE BREAST CANCER
INSTITUTION:
Olivia Newton-John Cancer Research Institute (ONJCRI) & La Trobe University
CHIEF RESEARCHER:
Prof. Robin Anderson
SYNOPSIS:
Targeting pro-tumour immune cells to improve response to immunotherapy for triple-negative breast cancer patients.
2021 - 2023
MORE PRECISE RISK ESTIMATES FOR EARLY-STAGE BREAST CANCER
INSTITUTION:
The University of Melbourne/Peter MacCallum Cancer Centre
CHIEF RESEARCHER:
Dr. Peter Savas
SYNOPSIS:
This research will study how different changes in the DNA in the tumours of over 11,000 patients affect the chance of the cancer coming back after surgery.
2021 - 2023
PRECISION TARGETING OF BREAST CANCER FIBROSIS TO BOOST EFFICIENCY OF CHEMOTHERAPY
INSTITUTION:
The Garvan Institute of Medical Research
CHIEF RESEARCHER:
Dr. Thomas Cox
SYNOPSIS:
Dr Cox and his team have generated exciting data to identify a critical enzyme (Peroxidasin) which is involved in the formation of the scar-like matrix in breast cancer.
2021 - 2023
FINDING TREATMENT FOR RIBOCICLIB RESISTANT BREAST CANCER USING PERSONALISED MEDICINE AND BIOSENSOR TECHNOLOGY
INSTITUTION:
The Garvan Institute of Medical Research
CHIEF RESEARCHER:
Prof. Paul Timpson
SYNOPSIS:
Our ultimate goal is to have the design of an early phase clinical trial conceptually established and pre-clinically validated within the duration of this grant.
2021 - 2023
A NEW IMMUNOTHERAPY APPROACH TO TARGET TRIPLE-NEGATIVE BREAST CANCER
INSTITUTION:
Queensland Institute of Medical Research Berghofer
CHIEF RESEARCHER:
Prof. Kum Kum Khanna
SYNOPSIS:
This research will improve our knowledge about the factors that inhibit growth and recurrence of breast cancer, which is critical to unlocking better treatment strategies. ...
2020 - 2023
CURING THE INCURABLE: PATIENT-CENTRED DIAGNOSTICS GUIDING THE SELECTION OF THERAPIES FOR METASTATIC BREAST CANCER
INSTITUTION:
Olivia Newton-John Cancer Research Institute (ONJCRI) & La Trobe University
CHIEF RESEARCHER:
Dr Belinda Yeo and Dr Delphine Merino
SYNOPSIS:
A formal translational study to demonstrate the value of analysing patient samples in both early stage and advanced breast cancer, ...
